Innovent's PD-1 candidate under Chinese review, company reports Phase II data

Innovent Biologics Inc. (Suzhou, China) said the State Drug Administration (formerly CFDA) accepted

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE